Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

Keywords

Histone deacetylase, Epigenetics, Histone, Context (archaeology), Vorinostat

References

• Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancerCliment Forner — 1999
• Multiple N-CoR Complexes Contain Distinct Histone Deacetylases*伸二 河辺, 由美子 小芝, 達雄 岡島 — 2001
• Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis.William Shakespeare — 2004
• Analysis of checkpoint responses to histone deacetylase inhibitors.Heather Beamish, Robyn Warrener, Brian Gabrielli — 2004
• Histone deacetylase inhibitors: assays to assess effectiveness in vitro and in vivo.Victoria M. Richon, Xianbo Zhou, J. Paul Secrist — 2004
• Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.Steven D. Gore, Li-Jun Weng, William D. Figg — 2002
• Shaping the nuclear action of NF-κBLin‐Feng Chen, Warner C. Greene — 2004
• Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824.Peter Atadja, Meier Hsu, Paul Kwon — 2004
• Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences.Jay L. Grisolano, Robin L. Wesselschmidt, Pier Giuseppe Pelicci — 1997
• The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation.Carine Van Lint, Stéphane Emiliani, Eric Verdin — 1996
• Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.Wm. Kevin Kelly, Victoria M. Richon, Owen A. O’Connor — 2003
• The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.Roberto R. Rosato, Jorge A. Almenara, Steven Grant — 2003
• Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repressionG. Lagger, Dónal O’Carroll, Martina Rembold — 2002
• Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines.Keith B. Glaser, Michael J. Staver, Jeffrey F. Waring — 2003
• Therapeutic implications of cancer stem cells.Muhammad Al‐Hajj, Michael W. Becker, Max S. Wicha — 2004
• Leukemia-Associated Fusion Proteins: Multiple Mechanisms of Action to Drive Cell TransformationAlessandra Insinga, Pier Giuseppe Pelicci, Saverio Minucci — 2005
• Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis.Ping Zhu, Elke Martin, Jörg Mengwasser — 2004
• Histone-deacetylase inhibitors: novel drugs for the treatment of cancerRicky W. Johnstone — 2002
• p300/CBP and cancerN. Gopalakrishna Iyer, Hi̇lal Özdağ, Carlos Caldas — 2004
• Post-translational modification of p53 in tumorigenesisAnn M. Bode, Zigang Dong — 2004

Cited by

• Defective apoptosis underlies chemoresistance in ovarian cancer.Karen M. Hajra, Lijun Tan, J. Rebecca Liu — 2008
• Azumamides A-E: histone deacetylase inhibitory cyclic tetrapeptides from the marine sponge Mycale izuensis.Yoichi Nakao, Satoru Yoshida, Shigeki Matsunaga — 2006
• Development of histone deacetylase inhibitors for cancer treatmentPer Bergling — 2007
• Histone modifications as markers of cancer prognosis: a cellular view임유진, 정은숙, 이은진 — 2007
• Hepatitis B virus X protein induces the expression of MTA1 and HDAC1, which enhances hypoxia signaling in hepatocellular carcinoma cellsGeorge deLucenay Leon — 2008
• Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases.幸之助 鈴木 — 2008
• Deacetylation of nonhistone proteins by HDACs and the implications in cancer.Lirong Peng, Edward Seto — 2011
• Transcriptional control of human p53-regulated genesAntonio Cózar — 2008
• Histone Deacetylase 8 in Neuroblastoma TumorigenesisÁngel Amado Calvo Calvo — 2009
• Targeting of HDAC8 and investigational inhibitors in neuroblastomaRoberto Rubio-Fabián — 2009
• Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Purα‐mediated decrease in androgen receptor levelsNadia Jamaleddine — 2010
• Ubiquitin B: an essential mediator of trichostatin A-induced tumor-selective killing in human cancer cellsR Olaopa Olawale, Ogundari Ibikunle. O, Fagbohun Francis. O — 2010
• Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll‐like receptor 4 agonist LPSManuel Paz de Santos — 2010
• Epigenomics and ovarian carcinomaAndrew P. Santoso — 2010
• Increasing CD44+/CD24- tumor stem cells, and upregulation of COX-2 and HDAC6, as major functions of HER2 in breast tumorigenesisKazumi Kubo — 2010
• Parthenolide, a Sesquiterpene Lactone, Expresses Multiple Anti-cancer and Anti-inflammatory ActivitiesFernando Sáez Vacas — 2011
• Regenerative medicine and tissue engineering in orthopaedic surgery.S.J. Edmundson — 2011
• The impact of plant-pathogen studies on medicinal drug discovery.金少策 — 2012
• Spiro[chromane‐2,4′‐piperidine]‐Based Histone Deacetylase Inhibitors with Improved in vivo Activity森さつき — 2012
• HDAC6 as a target for antileukemic drugs in acute myeloid leukemia.Lisa Gapinske — 2012

Related papers

• Antitumor Effects of the Histone Deacetylase Inhibitor Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Human Retinoblastoma Cell Lines: Therapeutic ImplicationsV. Poulaki, Vassiliki Kotoula, Constantine S. Mitsiades — 2008
• The histone deacetylase inhibitor vorinostat induces calreticulin exposure in childhood brain tumour cells in vitroJürgen Sonnemann, Stephanie Greßmann, Jonathan Becker — 2010
• Progress in clinical trial of histone deacetylase (HDAC) inhibitors for non-small cell lung cancers*Xingsheng Hu, Lin Wang, Lin Lin — 2014
• A structural insight into hydroxamic acid based histone deacetylase inhibitors for the presence of anticancer activity.Harish Rajak, A. Jonathan Singh, Kamlesh Raghuwanshi — 2013
• Vorinostat, a Histone Deacetylase Inhibitor, as a Candidate Therapy to Treat Liver Pathology in a Niemann-Pick type C Disease Mouse ModelNatalie Hammond — 2016
• Synthesis, characterization, and vitro evaluation of new materials in vorinostat analogs containing biomoleculesAmeer H. Alwash, Noor H. Naser — 2021
• Histone Deacetylase 2 (HDAC2) Inhibitors Containing BoronPoya Kavianpour, Madeleine C. M. Gemmell, Jan Kahlert — 2020
• Pharmacology and clinical evaluation of vorinostat,a histone deacetylase inhibitorFU De-xing — 2009
• Potential non-oncological applications of histone deacetylase inhibitors.Katherine Ververis, Tom C. Karagiannis — 2011
• Design, synthesis, and biological evaluation of N-hydroxycinnamamide/salicylic acid hybrids as histone deacetylase inhibitorsTao Tao, You, Ke — 2014